Evotec (EVO) Q2 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.13

Estimate

-$0.04

Surprise

-225.0%

Score today

4.3/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Evotec (EVO) reported a wider loss than forecast — adjusted EPS of -$0.13 against the -$0.04 estimate (a 225.0% shortfall).

• Evotec Q2 EPS $(0.15) Misses $(0.06) Estimate, Sales $166.802M Miss $212.370M Estimate — benzinga, 2026-08-13
• Evotec Affirms FY2026 Sales Guidance of $667.470M-$714.310M vs $673.750M Est — benzinga, 2026-08-13

TrendMatrix currently rates EVO Sell at 4.3/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's -225.0% surprise compares with a -34.9% four-quarter average. Next scheduled report: 2026-11-05.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$1.56

Price target

$3.60

Stop

$1.46

Upside to target

+130.8%

Reward-to-risk

15.3:1

Model outputs from TrendMatrix’s engine as of 2026-09-26 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Drug Manufacturers - Specialty & Generic

Market cap

$543.7M

P/E (fwd)

-8.1

52-week range

$1.50–$4.27

Off 52-week high

63.5%

RSI (14)

21

Volume vs avg

0.14×

Score today

4.3/10